The FDA on December 16, 2022, approved ADSTILADRIN® (Nadofaragene firadenovec-vncg) for adult patients with high-risk Bacillus Calmette-Guérin (BCG) unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with Carcinoma in Situ (CIS), with or without papillary tumors. ADSTILADRIN® is a product of Ferring Pharmaceuticals.
Other Pages – Bottom Ad
Advertisement
Subscribe
